Oncotelic Partners with TechForce Robotics for PDAOAI-Enhanced Robotics Platform Commercialization

Oncotelic Therapeutics, Inc. has partnered with TechForce Robotics to commercialize a PDAOAI-enabled, GMP-compliant robotics platform. The initiative combines Oncotelic's AI capabilities with TechForce's robotics expertise, aiming to automate critical workflows in regulated environments.

This platform is designed for automated material handling, real-time monitoring, and enhanced compliance workflows, which may reduce manual processes and contamination risks. The partnership follows a joint development agreement, establishing a framework for production scaling and commercialization. The collaboration is timely as pharmaceutical manufacturers increasingly seek to integrate automation solutions to meet regulatory demands, suggesting potential shifts in operational strategies across the industry.